--- title: "Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $50.00 at Citigroup" description: "Citigroup has raised its price target for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from $45.00 to $50.00, maintaining a \"buy\" rating. This suggests a potential upside of 31.86% from the cur" type: "news" locale: "en" url: "https://longbridge.com/en/news/261732827.md" published_at: "2025-10-18T15:42:25.000Z" --- # Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $50.00 at Citigroup > Citigroup has raised its price target for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from $45.00 to $50.00, maintaining a "buy" rating. This suggests a potential upside of 31.86% from the current price. Other analysts have also adjusted their ratings, with Wells Fargo increasing its target to $45.00 and Jefferies to $54.00. KNSA shares traded at $37.92, with a market cap of $2.81 billion. The company reported earnings of $0.23 per share, exceeding estimates, and has a consensus rating of "Moderate Buy" with an average target of $46.86. Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target raised by analysts at Citigroup from $45.00 to $50.00 in a report released on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's price objective suggests a potential upside of 31.86% from the company's current price. Several other equities analysts also recently commented on KNSA. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $46.86. **View Our Latest Stock Analysis on Kiniksa Pharmaceuticals International** ## Kiniksa Pharmaceuticals International Stock Performance Shares of KNSA traded down $1.00 during mid-day trading on Friday, reaching $37.92. The stock had a trading volume of 106,006 shares, compared to its average volume of 631,065. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 948.49 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.43. The business has a fifty day moving average of $35.72 and a 200 day moving average of $29.60. Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year. ## Insider Buying and Selling at Kiniksa Pharmaceuticals International In related news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider owned 9,415 shares of the company's stock, valued at $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares in the company, valued at approximately $1,324,303.24. The trade was a 22.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 596,839 shares of company stock worth $20,357,964 in the last ninety days. Company insiders own 53.48% of the company's stock. ## Institutional Investors Weigh In On Kiniksa Pharmaceuticals International Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $301,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $42,000. Finally, AMI Asset Management Corp raised its stake in shares of Kiniksa Pharmaceuticals International by 50.3% in the first quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock. ## About Kiniksa Pharmaceuticals International (Get Free Report) Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. ## Featured Articles - Five stocks we like better than Kiniksa Pharmaceuticals International - Upcoming IPO Stock Lockup Period, Explained - Oracle’s AI Profits Look Slim—Are NBIS and CRWV at Risk Too? - Insider Trading - What You Need to Know - Abbott Laboratories' October Price Plunge Is a Signal to Buy - How to Start Investing in Real Estate - Why Wells Fargo's Turnaround Just Hit High Gear *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now? Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list. While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [KNSA.US - Kiniksa Pharmaceuticals](https://longbridge.com/en/quote/KNSA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Kiniksa Pharmaceuticals｜8-K：2025 财年 Q4 营收 2.02 亿美元超过预期 | | [Link](https://longbridge.com/en/news/276734283.md) | | 花旗：短期内看好铜价 料未来三个月触及每吨 1.4 万美元 | 花旗发布研报称，短期内看好铜价，预计未来三个月将触及每吨 14,000 美元，维持今年铜价每吨 13,000 美元的平均价格预测不变。认为短期内风险回报偏向看涨，投资者将趁低吸纳，春节后中国供应链补充库存将支撑铜价。预计去年铜终端使用消费同 | [Link](https://longbridge.com/en/news/276845819.md) | | 华尔街顶级分析师评级调整：Block 获上调，多邻国被下调 | 华尔街顶级分析师对多家公司进行了评级调整。Block 的评级由摩根士丹利上调至增持，目标价从 72 美元升至 93 美元。西南航空、霍尼韦尔、Palantir 和 Live Nation 也获得评级上调。相反，华纳兄弟探索的评级被 Benc | [Link](https://longbridge.com/en/news/277221851.md) | | 香港营销平台 Red Wisdom Creation IPO 定价 4-5 美元/股 筹资规模上调 47% 至 2800 万美元 | 香港多渠道营销平台 Red Wisdom Creation 计划以每股 4-5 美元的价格发行 630 万股股票，筹资 2800 万美元，较之前的 1900 万美元上调 47%。该公司专注于年轻消费者，提供网红营销和精准营销服务，计划在纳斯 | [Link](https://longbridge.com/en/news/277147860.md) | | 兴业证券：上调汇丰控股至 “买入” 评级 2025 年业绩强劲 | 兴业证券上调汇丰控股评级至 “买入”，预计 2025 年净利息收入为 348 亿美元，较 2024 年增加 21 亿美元，净利息收益率为 1.59%。公司 2026 年银行业务净利息收益预期不少于 450 亿美元，2026-2028 年平均 | [Link](https://longbridge.com/en/news/277133663.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.